Wave Life Sciences

We’re heading to #OPTBoston this week, where our team will be sharing perspectives across multiple sessions spanning discovery through development. We’re looking forward to exchanging real‑world insights and connecting on how to translate cutting‑edge science into transformative medicines. See our full speaking schedule below and find more details here: optcongress.com

Our President & CEO, @PaulBolno, will be at #SXSW with @DrAngelaFitch and @ObesityAction's @JNadglowskiOAC speaking on a panel about the Renaissance in Obesity Treatment Innovation. If you’re in Austin, join in for a dynamic discussion challenging misconceptions about obesity and why effective treatments must focus on improving body composition. At Wave, we’re focused on driving fat loss without muscle loss, with the potential for 1-2x yearly dosing. We look forward to a conversation about what WVE-007 could mean for the future of obesity care. Details: lnkd.in/ePBPC5A3

We are pleased to announce the acceptance of a late-breaking oral presentation on WVE-006 (GalNAc-RNA editing) for AATD at #ATS2026! Read more here: ir.wavelifesciences.com/news-releases/… $WVE

Today we announced our 4Q and full year 2025 earnings update. Read the press release and find the link to our 8:30 a.m. conference call here: ir.wavelifesciences.com/news-releases/… This update includes the latest on our INLIGHT clinical trial of WVE-007 (INHBE GalNAc-siRNA) in individuals living with overweight or obesity and our RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing oligonucleotide) for individuals living with AATD, as well as WVE-008 (GalNAc-RNA editing oligonucleotide) for PNPLA3 I148M liver disease. $WVE

This Thursday at 2:40 p.m. ET, our President & CEO, @PaulBolno, is participating in an analyst-led fireside chat at the virtual @Oppenheimer 36th Annual Healthcare Life Sciences Conference. Register and listen here: event.summitcast.com/view/CTtthLh2B… $WVE

On Thursday, February 26, we will review our 4Q and full year 2025 financial results and provide business updates. Register and listen to the webcast here: ir.wavelifesciences.com/news-releases/… $WVE

Our President & CEO @PaulBolno is presenting at #JPM26 today at 2:15 p.m. PT / 5:15 p.m. ET. Don’t miss this look at what’s next for Wave, including our 2026 strategic priorities and how we’re advancing our leading RNA medicines platform. Join the live webcast here: jpmorgan.metameetings.net/events/healthc… #JPM2026 $WVE

Today we highlighted our strategic priorities for 2026, including accelerating development of WVE-007, our investigational INHBE GalNAc-siRNA for obesity, and rapidly advancing our RNA editing portfolio. Highlights from today’s update include: ➡️ We expect to initiate a Phase 2a multidose portion of INLIGHT (WVE-007) in individuals living with obesity with higher BMI and comorbidities in the first half of 2026 ➡️ We expect to initiate new trials for WVE-007 as an add-on to incretin and as maintenance post-incretin, in 2026 ➡️ We are extending our leadership in RNA editing with multiple data updates for WVE-006 on track for 2026 and our anticipated CTA filing for WVE-008 on track for this year as well Read more here: ir.wavelifesciences.com/news-releases/… #JPM2026 #JPM26

Today we shared exciting interim data from our ongoing INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) for obesity. A single dose resulted in an improvement in body composition with fat loss similar to GLP-1 at three months without muscle loss. See the presentation: ir.wavelifesciences.com/static-files/a… More key highlights ⬇️ ➡️ Following a single subcutaneous 240 mg dose, WVE-007 improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2% increase in lean mass (4.0 lbs; p=0.01), with no statistically significant changes in the placebo group ➡️ Sustained and robust suppression of serum Activin E supports expectations for continued improvements in body composition, further fat loss, and preserved muscle, with once or twice-yearly dosing ➡️ Generally safe and well tolerated with only mild treatment related adverse events and no clinically meaningful changes in clinical laboratory measurements, including lipid profiles or liver function tests ➡️ Planning underway for Phase 2 trials evaluating WVE-007 both as a monotherapy and an add-on therapy to incretins in populations with higher BMI and related co-morbidities, and as maintenance post-incretin treatment ➡️ Further clinical data updates expected in 1Q 2026, including six-month follow-up from the 240 mg single-dose cohort and three-month follow-up from the 400 mg single-dose cohort

Today we announced positive interim clinical data from the INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) for obesity demonstrating that a single 240 mg dose improved body composition with fat loss similar to GLP-1 at three months, without muscle loss. $WVE Read the press release: ir.wavelifesciences.com/news-releases/… Join us at 8:30 a.m. ET for an investor webcast: …nical-data-dec-2025.open-exchange.net

We are hugely grateful to @WaveLifeSci for supporting our 2025 Family Gathering. Over 170 members of the Huntington’s disease community joined us in Glasgow along with health and social care practitioners and researchers for a wonderful day of connection, learning and friendship.

Our President and CEO, @PaulBolno, will be participating in both an analyst-led fireside chat and the “Advanced Approaches to Cardiometabolic Diseases” panel at the @Jefferies London Healthcare Conference on Thursday, November 20. Save the date and register for the fireside chat webcast here: wsw.com/webcast/jeff33… #JefferiesHealthcare $WVE

For over a decade, we’ve been driven by our commitment to Reimagine Possible for patients. Starting with Greg Verdine’s founding vision to challenge convention and push the boundaries of innovation, we have combined best-in-class chemistry, human genetic insights, and novel biology to build a multimodal pipeline of stereopure oligonucleotides that continues to translate in the clinic. Today, we celebrate 10 years on @Nasdaq, and recognize our founders, our employees, and all the study participants, families, and clinical teams that inspire our work every single day. Here’s to the next decade of breakthroughs!

Introducing WVE-008, a potential first-in-class, disease modifying therapy for the treatment of PNPLA3 I148M liver disease, which builds on the clinical translation of our RNA editing capability. Watch our recent Research Day presentation to learn more: …esearch-day-oct2025.open-exchange.net $WVE

Today we announced our 3Q 2025 earnings update. We’re incredibly encouraged by the progress we’ve made across our INLIGHT trial for obesity and our RestorAATion-2 trial for AATD. Looking forward, we have a tremendous opportunity to build on our strong momentum as we continue to reimagine what's possible for patients. Listen to the webcast here: …arter-2025-earnings.open-exchange.net/registration $WVE

We’re attending #TLM25 to present new preclinical data (poster #4025). Visit us at booth #948 to learn more about our RNA editing programs. @AASLDtweets #AASLD

We are incredibly excited to be observing potent, durable dose-dependent Activin E reductions with a single dose of WVE-007 in the first three cohorts of our INLIGHT clinical trial in obesity. With multiple catalysts for this program ahead, here’s what to expect. You can also view our full Research Day presentation: ir.wavelifesciences.com/static-files/4…

We’re in Atlanta at @ObesityWeek 2025! Join us Thursday at 2:30 p.m. at Poster-710 to learn more about the therapeutic potential of WVE-007 for obesity. Read the press release here: ir.wavelifesciences.com/news-releases/… #ObesityWeek #OW2025

On Monday, November 10, we will present our 3Q earnings update. Register and listen to the webcast here: …arter-2025-earnings.open-exchange.net/registration $WVE

At our annual Research Day, we shared a positive target engagement update from the INLIGHT clinical trial of WVE-007, our GalNAc INHBE-siRNA designed to reduce Activin E, inducing fat loss while preserving muscle. We’re excited about the potential impact this program could have for patients and the future of obesity care! Learn more: ir.wavelifesciences.com/static-files/4…